Novocure's TRIDENT trial misses primary endpoint in glioblastoma

June 18, 2026 7:00 AM

Novocure (NASDAQ: NVCR) announced that its Phase 3 TRIDENT trial failed to meet its primary endpoint, showing no statistically significant ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found